Product Details

Verclo-A Capsules combine two complementary antiplatelet agents in a single formulation for the secondary prevention of atherothrombotic events. Specifically, each capsule delivers Clopidogrel and Aspirin at 75mg each. As a result, it offers simplified, dual antiplatelet therapy for patients with established cardiovascular disease.

The capsules combine:

• Clopidogrel Bisulfate IP (75mg) – A P2Y12 receptor antagonist that inhibits ADP-induced platelet aggregation. Consequently, it reduces the risk of thrombotic events such as heart attack and stroke.
• Aspirin IP (75mg) – A cyclooxygenase (COX) inhibitor that irreversibly blocks thromboxane A2 production in platelets. As a result, it provides additional antiplatelet effect, complementing Clopidogrel’s mechanism for broader thrombotic protection.

Physicians prescribe Verclo-A for patients with established coronary artery disease, prior myocardial infarction, or stroke, where dual antiplatelet therapy is indicated for secondary prevention. In addition, its single-capsule format simplifies the medication regimen and supports better patient adherence compared to taking two separate tablets. Because of this profile, Verclo-A suits cardiology practices and secondary prevention programs managing patients at high cardiovascular risk.

Key Features:

• Overall, this combination formulation guarantees pharmaceutical-grade purity across both actives
• Additionally, the single-capsule format simplifies dosing and supports patient adherence
• Furthermore, each capsule delivers precise, validated dosage accuracy at 75mg + 75mg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, blister packaging protects capsule integrity against light and moisture
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, cardiology clinics, and pharmacies